Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
NCT ID NCT06863233
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a PET/CT scan using an investigational tracer called zirconium Zr 89 crefmirlimab berdoxam can safely and effectively spot CD8+ T cells—key immune cells that attack cancer—in people with metastatic non-small cell lung cancer. Participants are already enrolled in a separate engineered TIL therapy study and will receive up to four tracer infusions followed by scans to see how these immune cells change before and after treatment. The goal is to learn if this imaging method can help monitor the body's immune response during TIL therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zirconium Zr 89 crefmirlimab berdoxam, a radiotracer used with PET/CT scans to detect CD8+ T cells
- What this could lead to
- If successful, this imaging approach could help doctors see how well TIL therapy is working in real time, potentially guiding treatment decisions for lung cancer.
- What could go wrong
- This is a very early, small study (5 participants) focused on imaging, not treatment. The tracer may not accurately reflect immune response, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Bergen (Consent Only)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All protocol activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)
RECRUITINGUniondale, New York, 11553, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Consent Only)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester (Consent only)
RECRUITINGHarrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge (Consent Only)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?